FSH therapy for idiopathic male infertility: four schemes are better than one

Abstract Objective The aim of this article is to propose an algorithm that aids the clinician to choose the best therapeutic scheme of follicle-stimulating hormone (FSH) in the treatment of men with idiopathic infertility, based on testicular volume (TV) and serum total testosterone concentrations; highlighting the potential role of additional therapy with hCG in a sequential temporal scheme. Materials and methods We subdivided patients in four clinical groups: patients with normal TV and serum testosterone concentrations (A); patients with normal TV and reduced serum testosterone concentrations (B); patients with reduced TV and serum testosterone concentration (C); patient with low TV e normal serum testosterone concentrations (D). Then, we administered to each group a specific therapeutic scheme. Group A: treated with FSH alone for at least 3 months; group B: treated with hCG alone twice a week for 3 months and addition of FSH for poor responders (unmodified sperm parameters); group C: treated ab initio with FSH and hCG until the pregnancy was reached; group D: treated with FSH alone for 3 months and addition of hCG for moderate poor responders (increased TV but unmodified sperm parameters) or second cycle of FSH for 3 months for severe poor responders (unmodified TV and sperm parameters). After 6 months we evaluated the therapeutic response in term of sperm parameters normalization rate, spontaneous pregnancy rate, and sperm DNA fragmentation normalization rate. Results 40% of patients became normozoospermic after treatment, while 30% achieved spontaneous pregnancy. B was the group that best responded to treatment in terms of normalization of seminal parameters; while the highest spontaneous pregnancy rate was obtained from the D group. B group also obtained the highest sperm DNA fragmentation normalization rate. Conclusions To date, no reliable predictors of response to treatment with FSH exist, but TV and serum testosterone concentrations can help the clinician to choose the best therapeutic scheme for men with idiopathic infertility. The groups treated with a sequential temporal scheme (B and D groups) showed better clinical results compared with two groups treated with conventional schemes (A and C groups).

[1]  A. Calogero,et al.  Current and emerging medical therapeutic agents for idiopathic male infertility , 2019, Expert opinion on pharmacotherapy.

[2]  R. Quinton,et al.  Fertility induction in hypogonadotropic hypogonadal men , 2018, Clinical endocrinology.

[3]  A. Calogero,et al.  Evaluation of testicular function in prepubertal children , 2018, Endocrine.

[4]  A. Lenzi,et al.  The use of follicle stimulating hormone (FSH) for the treatment of the infertile man: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS) , 2018, Journal of Endocrinological Investigation.

[5]  E. Baldi,et al.  Treatment with human, recombinant FSH improves sperm DNA fragmentation in idiopathic infertile men depending on the FSH receptor polymorphism p.N680S: a pharmacogenetic study. , 2016, Human reproduction.

[6]  G. Morgia,et al.  Late-onset hypogonadism: the advantages of treatment with human chorionic gonadotropin rather than testosterone , 2016, The aging male : the official journal of the International Society for the Study of the Aging Male.

[7]  D. Santi,et al.  FSH treatment of male idiopathic infertility improves pregnancy rate: a meta-analysis , 2015, Endocrine connections.

[8]  C. Manna,et al.  The use of r-hFSH in treatment of idiopathic male factor infertility before ICSI. , 2015, European review for medical and pharmacological sciences.

[9]  M. Maggi,et al.  Ultrasound of the male genital tract in relation to male reproductive health. , 2015, Human reproduction update.

[10]  L. Finos,et al.  Spermatid count as a predictor of response to FSH therapy. , 2014, Reproductive biomedicine online.

[11]  A. Calogero,et al.  Relationship between Testicular Volume and Conventional or Nonconventional Sperm Parameters , 2013, International journal of endocrinology.

[12]  E. Vicari,et al.  Follicle-stimulating hormone treatment in normogonadotropic infertile men , 2013, Nature Reviews Urology.

[13]  Jason M. White,et al.  Opioid maintenance: a comparative review of pharmacological strategies , 2007, Expert opinion on pharmacotherapy.

[14]  C. Foresta,et al.  Hormonal treatment of male infertility: FSH. , 2007, Reproductive biomedicine online.

[15]  C. Farquhar,et al.  Gonadotrophins for idiopathic male factor subfertility. , 2007, The Cochrane database of systematic reviews.